Alnylam, awaiting key study data, builds case for its next rare disease drug | BioPharma Dive

Retrieved on: 2022-01-21 17:21:21

Tags for this article:

Life Sciences

Health sciences

Health care

Orphan drugs

RNA interference

Alnylam Pharmaceuticals

Therapeutic gene modulation

Amyloidosis

Patisiran

Ionis Pharmaceuticals

Transthyretin

Familial amyloid polyneuropathy

Click the tags to see associated articles and topics

Alnylam, awaiting key study data, builds case for its next rare disease drug | BioPharma Dive. View article details on hiswai:

Excerpt

Dive Insight: For many years, the only treatments for TTR — a rare and potentially deadly disease — were liver transplants and a generic pill that ...

Article found on: www.biopharmadive.com

View Original Article